Branched Polymer Conjugates via Sortase Catalysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for synthesizing PEGylated conjugates face challenges such as low yield, purification difficulties, and chemical heterogeneity, which can compromise bioactivity and are further hindered by the immunogenicity of PEG, leading to adverse reactions and reduced efficacy of therapeutic peptides and proteins.
Innovation Solution
The development of molecule-polymer conjugates using branched polymers with backbones and side chains, specifically conjugated via sortase-catalyzed polymerization, to reduce or eliminate antigenicity and immunogenicity, thereby enhancing the circulation half-life and stability of therapeutic molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional PEGylation methods are used to increase circulation half-life and stability, then the therapeutic molecule gains extended circulation time, but the conjugate exhibits chemical heterogeneity and low yield due to steric hindrance and promiscuous distribution of reactive groups
Solution Approach 1:
The patent applies local quality by introducing a sortase A recognition sequence at a specific local site on the therapeutic molecule, enabling site-specific conjugation. This localized modification approach ensures that the polymer attaches at a predetermined position rather than randomly throughout the molecule, thereby achieving homogeneous conjugates with defined structure while maintaining extended circulation half-life
Solution Approach 2:
The patent employs sortase A enzyme as an intermediary to facilitate the conjugation reaction. The enzyme specifically recognizes the sortase A recognition sequence and catalyzes the attachment of the polymer in a controlled manner, enabling high-yield production of homogeneous conjugates while avoiding the steric hindrance and promiscuous distribution problems associated with conventional direct conjugation methods
2Object-affected harmful factors
If conventional PEGylation methods are used to reduce immunogenicity, then the therapeutic molecule gains reduced antigenicity, but pre-existing anti-PEG antibodies induce adverse reactions and accelerate blood clearance
Solution Approach 1:
The patent applies parameter changes by substituting the conventional PEG polymer with a poly(oligoethylene glycol) polymer featuring modified structural parameters including oligomeric repeating units and controlled molecular weight. This parameter modification results in a polymer that maintains the stealth properties and extended circulation half-life while significantly reducing recognition by pre-existing anti-PEG antibodies, thereby eliminating adverse immunogenic reactions
3Duration of action of moving object
If conventional PEGylation methods are used to achieve sustained delivery, then the therapeutic molecule gains extended circulation time, but frequent injections and peak-to-valley fluctuation persist due to insufficient half-life extension
Solution Approach 1:
The patent applies composite materials by creating a conjugate composed of the therapeutic molecule combined with poly(oligoethylene glycol) polymer. This composite structure integrates the therapeutic agent with the stealth polymer to achieve synergistic effects including extended circulation half-life, reduced immunogenicity, and sustained delivery, thereby enabling less frequent dosing and improved patient compliance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in molecule-polymer conjugates with increased stability, reduced antigenicity, and improved bioavailability, minimizing interactions with pre-existing anti-PEG antibodies, leading to more effective and safer therapeutic delivery.
Implementation Method 1
conjugated via sortase-catalyzed polymerization
Data Source
AI summary
Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.